 |
|
|
| |
Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
|
| |
| |
EASL 2023 June 23 Vienna
Ohad Etzion1, Saeed Sadiq Hamid2, Tarik Asselah3, George Sebastian Gherlan4, Adela Turcanu5, Tsarynna Petrivna6, Lisa Weissfeld7, Ingrid Choong8, Colin Hislop8, David Apelian8, Maria Buti9, Liana Gheorghe10, Elena Laura Iliescu10, Natalia Voronkova11, Natalia Barsukova, Soo Aleman12, Jordan J. Feld13, Nancy S Reau14, Maurizia Brunetto15, Pietro Lampertico16, Theo Heller17, Chris Koh17, Cihan Yurdaydin18, Jeffrey Glenn19.
|
| |
|
|
|
|
|
